Major Adverse Cardiovascular Events
12
2
2
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
Total Arterial vs. Mixed Grafting in Left Coronary CABG
Preoperative Statin Use and Major Adverse Cardiovascular Events in Liver Transplant Recipients
Relationship Between RAR and MACEs in AMI-CS Patients During Hospitalization
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines
CCTA Improves Clinical Management of Stable Chest Pain
Predictive Value of Systolic Rise Time of the Plantar Arch on the Risk of Major Adverse Limb Events (MALE) and Major Adverse Cardiovascular Events (MACE) in Peripheral Artery Disease (PAD) at Critical Ischaemia Stage
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)
Prognostic Value of Non-invasive Index of Endothelial Function.
Prognostic Accuracy of the HEART Score in Undifferentiated Chest Pain: A Multicenter Validation Study
Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.
CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)
Pre-discharge vs. Early Post-discharge Stress Testing and GRACE Score for Safe Discharge of ACS-patients With a Negative Hs-troponin T Result